Allergan Unlimited Company, formerly Allergan Limited, is an Ireland-based pharmaceutical company. The Company is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. The Company's products primarily focus on four key therapeutic areas, including medical aesthetics, eye care, central nervous system and gastroenterology.

Employees

Sector

Pharmaceuticals

More about the company

Oct. 21	Allergan Aesthetics presents its latest scientific advances
Sep. 29	Abbvie Through Allergan Aesthetics Receives Health Canada Authorization for Boey for Frown Lines	CI

Market Cap	63.66B 56.85B 52.52B 47.59B 89.04B 6,043B 90.51B 632B 250B 3,166B 239B 234B 9,982B	P/E 2018	-8.76x	P/E 2019	-11.9x
Enterprise Value	80.96B 72.3B 66.79B 60.53B 113B 7,686B 115B 804B 318B 4,027B 304B 297B 12,696B	EV / Sales 2018	4.24x	EV / Sales 2019	4.98x
Free-Float	99.9%	Yield 2018	2.15%	Yield 2019	1.55%

Oct. 21	Allergan Aesthetics presents its latest scientific advances
Sep. 29	Abbvie Through Allergan Aesthetics Receives Health Canada Authorization for Boey for Frown Lines	CI
Sep. 17	Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications	CI
Sep. 15	Allergan Aesthetics Introduces the FACTS Principles for Exosome-Based Skincare Technologies	CI
Sep. 01	Allergan Aesthetics Launches Skinmedica Barrier Calming Cream and Ha5 Hydra Collagen Facial Mist	CI
Apr. 07	Allergan Aesthetics Opens New Ami Training Center in Austin	CI
Mar. 31	Allergan Aesthetics Announces Fourth Annual CoolMonth With Deals On CoolSculpting	CI
Mar. 30	Allergan Aesthetics Presents Findings on Safety and Efficacy of Repeat Trenibote Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors At the 2026 American Academy of Dermatology Meeting	CI
Mar. 19	Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions	CI
Mar. 04	Allergan Aesthetics Shares Medical Weight Loss Data and the Changing Profile of Patients	CI
Nov. 12	Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence	CI
25-09-25	AllAllergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality At AMWC Dubai	CI
25-08-19	Allergan Aesthetics Unveils Its Newest Hydration Hero	CI

24-04-01	Court Dismisses Class Action Against Biopharmaceutical Company For Failing To Disclose Progress Of Competitor; Second Circuit Affirms Dismissal Of Putative Class Action Against Allergan; Eleventh Circuit Affirms That "Toxic" Lender Qualified As A "Dealer" Under The Exchange Act Due To High-Volume Trading; Delaware Court Of Chancery Invalidates Governance Rights In Stockholder Agreement	AQ
22-04-20	Allergan, an AbbVie Company, to Present New Data from its Eye Care Portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting	AQ
22-04-06	Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY 1.25% in Adults with Age-Related Blurry Near Vision	AQ
22-03-22	AbbVie and Allergan Aesthetics to Present New Research Across Dermatology Portfolio at 2022 AAD Annual Meeting	AQ
21-12-10	Allergan - VUITY 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry near Vision, is Now Available	AQ

Oct. 21	Allergan Aesthetics présente ses dernières avancées scientifiques
21-04-20	Planète Bourse : La revue de presse du mardi 20 avril 2021
20-05-07	EN DIRECT DES MARCHES : Air France KLM, ArcelorMittal, Legrand, Natixis, Peugeot, Eurofins, Zalando, Facebook...
20-05-07	La Chine repart, mais Washington veille
20-05-06	EN DIRECT DES MARCHES : Danone, Sanofi, Crédit Agricole, Arkema, Neoen, Eurofins, BMW, Novo Nordisk...

Actavis Inc Stock NYSE

Stocks

US9426831031

Pharmaceuticals

Valuation: Actavis Inc

Latest news: Actavis Inc

Press Releases: Actavis Inc

News in other languages: Actavis Inc

Managers and Directors: Actavis Inc

Other Pharmaceuticals

Financials

Company Profile

Director	Title	Age	Since
Scott Reents BRD	Director/Board Member	-	2020-05-07
Ryan Quigley BRD	Director/Board Member	-	2020-05-07
Andres Rodrigo BRD	Director/Board Member	-	2020-05-07

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	-2.54%	+1.31%	+55.10%	+120.84%	1,135B
JOHNSON & JOHNSON	-1.42%	+3.23%	+37.07%	+74.26%	636B
ABBVIE INC.	+0.16%	+0.08%	+25.14%	+97.36%	505B
ROCHE HOLDING AG	-0.31%	+3.09%	+43.92%	+64.55%	378B
MERCK & CO., INC.	-1.34%	-0.47%	+66.63%	+40.56%	358B
NOVARTIS AG	-0.68%	+2.65%	+22.46%	+51.48%	295B
ASTRAZENECA PLC	-1.20%	+3.04%	+2.62%	+26.97%	266B
AMGEN INC.	-1.79%	+1.57%	+49.97%	+60.87%	237B
GILEAD SCIENCES, INC.	-0.73%	-0.10%	+29.24%	+101.19%	193B
Average	-0.67%	+2.17%	+36.91%	+70.90%	444.93B
Weighted average by Cap.	-0.26%	+2.66%	+40.99%	+82.13%

	2018	2019
Net sales	15.79B 14.1B 13.02B 11.8B 22.08B 1,499B 22.45B 157B 62.05B 785B 59.25B 57.99B 2,476B	16.09B 14.37B 13.27B 12.03B 22.5B 1,527B 22.88B 160B 63.23B 800B 60.38B 59.1B 2,523B
Net income	-5.1B -4.55B -4.2B -3.81B -7.13B -484B -7.25B -50.59B -20.03B -253B -19.13B -18.72B -799B	-5.27B -4.71B -4.35B -3.94B -7.37B -500B -7.49B -52.33B -20.72B -262B -19.78B -19.36B -827B
Net Debt	21.89B 19.55B 18.06B 16.37B 30.62B 2,078B 31.12B 217B 86.04B 1,089B 82.15B 80.41B 3,433B	17.3B 15.45B 14.28B 12.94B 24.2B 1,643B 24.6B 172B 68.01B 861B 64.94B 63.56B 2,713B

End-of-day quote NYSE
- ^USD	-